Sign In
Buy IMAB
$4.63
+0 (+0%)
At Close: Apr 14, 2026
I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
08:00am, Wednesday, 10'th Mar 2021
- New Initiative is part of I-Mab's long-term strategy to drive innovation and scientific leadership in immuno-oncology - New collaborations signed will allow I-Mab access to cutting edge technology
Week In Review: Suzhou's Adagen Raises $140 Million In U.S. IPO To Develop Oncology Drugs
03:54pm, Sunday, 14'th Feb 2021
Adagene completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Antibe
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1
03:38pm, Sunday, 07'th Feb 2021
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab
05:27pm, Friday, 05'th Feb 2021
SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializat
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
08:00am, Friday, 05'th Feb 2021
SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
04:05pm, Monday, 25'th Jan 2021
SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the f
Week In Review: CANbridge Closes $43 Million E Round For Rare Disease Drugs
03:04pm, Sunday, 06'th Dec 2020
CANbridge Pharma completed a $43 million Series E financing that is a follow-on to its $98 million Series D round, announced in February. Pfizer and Germany's BioNTech announced their partnered mRNA C
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board
08:00am, Tuesday, 01'st Dec 2020
SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializat
Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPO
12:33pm, Sunday, 15'th Nov 2020
Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstrat
I-Mab to Hold Investor Call and Expand Clinical Data Analysis on Efficacy Signal of Lemzoparlimab from Phase 1 Clinical Trial
05:10am, Friday, 13'th Nov 2020
SHANGHAI and GAITHERSBURG, Md., Nov. 13, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializa
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
08:00am, Wednesday, 11'th Nov 2020
SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializa
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
08:05am, Tuesday, 27'th Oct 2020
SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercializa
AbbVie I-Mab Cancer Deal, And Other News: The Good, Bad And Ugly Of Biopharma
04:46am, Tuesday, 08'th Sep 2020
AbbVie inks multi-billion cancer deal with I-Mab. Chi-Med begins global phase III trial of cancer treatment.
Week In Review: I-Mab Partners CD47 With AbbVie In $2 Billion Deal
12:21pm, Sunday, 06'th Sep 2020
Shanghai's I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement.
I-Mab's (IMAB) CEO Joan Huaqiong Shen on Q2 2020 Results - Earnings Call Transcript
01:47pm, Monday, 31'st Aug 2020
I-Mab (NASDAQ:IMAB) Q2 2020 Results Earnings Conference Call August 31, 2020, 08:00 AM ET Company Participants Jingwu Zhang Zang - Founder, Honorary Chairman Joan Huaqiong Shen - CEO Jielun Zhu - CFO
